fa Obstetrics and Gynecology Obstetrics and Gynecology پژوهشي Original Research <span style="font-size:11pt"><span style="line-height:14.0pt"><span style="text-autospace:none"><span style="font-family:&quot;Calibri&quot;,sans-serif"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Background:</span></span></b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> Despite the advancement in thanatological research, stillbirth remains one of the most proscribed and misunderstood types of losses. Aim of our study was to compare the efficacy and safety of the combination of mifepristone and Misoprostol vs. Misoprostol alone for the induction of labor in antepartum stillbirth. </span></span></span></span></span></span><br /> <span style="font-size:11pt"><span style="line-height:14.0pt"><span style="text-autospace:none"><span style="font-family:&quot;Calibri&quot;,sans-serif"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Methods:</span></span></b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> This study recruited fifty-two pregnant individuals at a gestational age beyond 28 weeks who had been diagnosed with antepartum stillbirth. Participants allocated to group I received an oral dose of 200 mg of Mifepristone. Subsequently, after a 24-hour interval, patients were administered 50 mcg of Misoprostol orally every 4 hours, up to a maximum of four doses. In contrast, participants in group II were provided with a placebo of Tablet Calcium (500mg). Following the same 24-hour interval, they received a dose of 50 mcg of Misoprostol orally every 4 hours, for a maximum of four doses.</span></span></span></span></span></span><br /> <span style="font-size:11pt"><span style="line-height:14.0pt"><span style="text-autospace:none"><span style="font-family:&quot;Calibri&quot;,sans-serif"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Results:</span></span></b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> The mean (standard deviation) induction-to-delivery interval (IDI) in group I and group II were 8.6 (1.9) and 11.9 (3.7) hours, respectively (p <0.001). In group I, the mean (SD) total dosage of Misoprostol was 65.4 (30.9) milligrams, whereas in group II, it was 126.9 (45.2) milligrams. A significant difference was observed between the two groups in terms of the total dosage of Misoprostol (p <0.001).</span></span></span></span></span></span><br /> <span style="font-size:11pt"><span style="line-height:14.0pt"><span style="text-autospace:none"><span style="font-family:&quot;Calibri&quot;,sans-serif"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Conclusion:</span></span></b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> These results underscore the potential benefits of Mifepristone and Misoprostol in improving outcomes for individuals experiencing antepartum stillbirth. Further research is warranted to validate and expand upon these findings, with the ultimate goal of enhancing care and support for those affected by stillbirth.</span></span><b><span style="font-size:10.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="color:#006699"></span></span></span></b></span></span></span></span> Mifepristone, Misoprostol, Stillbirth 9 14 http://caspjrm.ir/browse.php?a_code=A-12-135-5&slc_lang=fa&sid=1 Bhallamudi Venkata Alekhya 10031947532846002368 10031947532846002368 No Usha Yadav drusha.yadav98@gmail.com 10031947532846002369 10031947532846002369 Yes 1Department of Obstetrics & Gynaecology, Deen Dayal Upadhyay Hospital, New Delhi, India Shashi Lata Kabra 10031947532846002370 10031947532846002370 No Soma Mitra 10031947532846002371 10031947532846002371 No Monika Suri Grover 10031947532846002372 10031947532846002372 No